Avelumab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-AVELUMAB |
|---|---|
| Type | Drug |
| Aliases | BavencioАвелумаб |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NK-T-NASAL DIS-UROTHELIAL |
| Sources | SRC-NCCN-BCELL-2025 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | Anti-PD-L1 monoclonal antibody (IgG1 with preserved ADCC) |
|---|---|
| Mechanism | Fully human IgG1 anti-PD-L1 antibody. Blocks PD-L1 binding to PD-1 and CD80, restoring T-cell antitumor immunity. The IgG1 isotype retains antibody-dependent cellular cytotoxicity (ADCC) — distinct from IgG4 anti-PD-L1 agents — relevant for NK-cell engagement in certain tumor types. |
| Typical dosing | 800 mg IV every 2 weeks (or 10 mg/kg q2w in older labeling). Premedication for first 4 infusions (paracetamol + diphenhydramine). |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Multi-indication anti-PD-L1: FDA-approved for metastatic Merkel cell carcinoma (JAVELIN Merkel 200), urothelial maintenance after platinum (JAVELIN Bladder 100), and 1L RCC + axitinib (JAVELIN Renal 101). In NK/T-cell lymphoma: phase 2 data (Kim 2020 Blood) showed ORR ~38% in r/r EBV-driven NK/T-NL exploiting EBV/PD-L1 signaling axis. Off-label for hematologic indications. Standard ICI immune- mediated AE management protocol applies (steroid taper, treatment hold thresholds per NCCN immunotherapy toxicity guidelines).
Used By
Regimens
REG-AVELUMAB-MAINTENANCE- Avelumab maintenance (urothelial post-platinum chemo)REG-AVELUMAB-MONO-NK-T- Avelumab monotherapy for r/r NK/T-cell nasal lymphoma (off-label)